Key facts
- This page summarizes Christopher Thomas Giordano's Form 4 filing for TENAX THERAPEUTICS, INC. (TENX).
- 2 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 15 Sep 2026, 21:38.
Christopher Thomas Giordano - 11 Sep 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)
- Reporting relationship
- CEO, Director
- Issuer ticker
- TENX
- Reported as of
- 11 Sep 2026
- Net transaction value
- +$20,087
- SEC form
- 4
- Accepted by SEC
- 15 Sep 2026, 21:38:58 UTC
- Prior SEC filing
- 14 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ S. Halle Vakani, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Thomas Giordano filed Form 4 for TENAX THERAPEUTICS, INC. (TENX) on 15 Sep 2026.
Change
- Previous filing in this sequence was filed on 14 Jul 2026.
- Current net transaction value: +$20,087.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001871714
Primary reporting owner
Giordano Christopher Thomas
- Relationship
- CEO, Director
- Address
- 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL
- Signature
- /s/ S. Halle Vakani, as Attorney-in-Fact
- Signature date
- 15 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TENX
transaction
Common Stock
Purchase
- Transaction value
- $11,250
- Shares
- +6,000
- Change %
- +53%
- Price
- $1.88
- Shares after
- 17,324
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
TENX
transaction
Common Stock
Purchase
- Transaction value
- $8,837
- Shares
- +4,850
- Change %
- +28%
- Price
- $1.82
- Shares after
- 22,174
- Date
- 15 Sep 2026
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TENX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 450,000
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 450,000
- Exercise price
- $13.30
- Footnotes
- F3
TENX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,400,000
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,400,000
- Exercise price
- $5.89
- Footnotes
- F4
TENX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 218
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 218
- Exercise price
- $3.55
- Footnotes
- F5
TENX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,241,500
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,241,500
- Exercise price
- $5.94
TENX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 125
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125
- Exercise price
- $992.00
- Footnotes
- F6
TENX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 157
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 157
- Exercise price
- $3152.00
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Footnote F3
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
Footnote F4
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
Footnote F5
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
Footnote F6
The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
Footnote F7
The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.